{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T10:25:51Z","timestamp":1762079151631},"reference-count":37,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2009,5,18]],"date-time":"2009-05-18T00:00:00Z","timestamp":1242604800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2009,8]]},"abstract":"<jats:sec><jats:title>Abstract<\/jats:title><jats:p><jats:bold>Background\u2002<\/jats:bold> Psoriasis vulgaris of the scalp has a significant psychosocial impact on individuals affecting their quality of life (QoL). A combination of calcipotriol and betamethasone dipropionate in a formulation suitable for treatment of scalp psoriasis has been developed.<\/jats:p><jats:p><jats:bold>Objective\u2002<\/jats:bold> To assess the impact of treatment with either calcipotriol plus betamethasone dipropionate scalp formulation or calcipotriol scalp solution on QoL in patients with scalp psoriasis (both within and between treatment groups).<\/jats:p><jats:p><jats:bold>Methods\u2002<\/jats:bold> This 8\u2010week, randomized, investigator\u2010blind study, compared the once\u2010daily, two\u2010compound scalp formulation (calcipotriol 50 \u00b5g\/g plus betamethasone 0.5\u00a0mg\/g as dipropionate; Xamiol<jats:sup>\u00ae<\/jats:sup>, LEO Pharma A\/S, Ballerup, Denmark) with twice\u2010daily calcipotriol scalp solution (50\u00a0\u00b5g\/mL; Daivonex<jats:sup>\u00ae<\/jats:sup>, LEO Pharma A\/S) in patients with scalp psoriasis of at least moderate severity covering\u00a0\u2265\u00a010% of the scalp. QoL was assessed (weeks 0, 2, 4, 8) using the 36\u2010item Short Form Health Survey (version 2; SF\u201036v2) and Skindex\u201016.<\/jats:p><jats:p><jats:bold>Results\u2002<\/jats:bold> Treatment with the two\u2010compound scalp formulation (<jats:italic>n<\/jats:italic>\u00a0=\u00a0207) resulted in significant improvements from baseline on the SF\u201036v2 (Physical Component Summary, <jats:italic>P\u00a0=<\/jats:italic>\u00a00.005, week 8; Mental Component Summary, <jats:italic>P\u00a0&lt;<\/jats:italic>\u00a00.05, weeks 2, 4, 8). A significant change from baseline in the calcipotriol scalp solution group (<jats:italic>n<\/jats:italic>\u00a0=\u00a0105) was seen only on the Mental Component Summary (<jats:italic>P\u00a0=<\/jats:italic>\u00a00.04, week 8). Change from baseline in Skindex\u201016 was significantly in favour of the two\u2010compound scalp formulation. Change was significant on both total score and individual scales.<\/jats:p><jats:p><jats:bold>Conclusion\u2002<\/jats:bold> The two\u2010compound scalp formulation was superior to calcipotriol scalp solution in improving QoL in patients with scalp psoriasis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conflict of interest declaration<\/jats:title><jats:p>J.P. Ortonne has served as a paid speaker and consultant for LEO Pharma.<\/jats:p><jats:p>C. Ganslandt is a salaried employee of LEO Pharma.<\/jats:p><jats:p>J. Tan served as a speaker, investigator and advisory board member for LEO Pharma and received honoraria from LEO Pharma for these activities.<\/jats:p><jats:p>P. Nordin served as a paid investigator for LEO Pharma in the clinical trial.<\/jats:p><jats:p>K. Kragballe has served as a paid speaker and consultant for LEO Pharma.<\/jats:p><jats:p>S. Segaert has served as a paid speaker, clinical investigator and consultant for LEO Pharma.<\/jats:p><\/jats:sec>","DOI":"10.1111\/j.1468-3083.2009.03221.x","type":"journal-article","created":{"date-parts":[[2009,5,18]],"date-time":"2009-05-18T15:16:58Z","timestamp":1242659818000},"page":"919-926","source":"Crossref","is-referenced-by-count":30,"title":["Quality of life in patients with scalp psoriasis treated with calcipotriol\/betamethasone dipropionate scalp formulation: a randomized controlled trial"],"prefix":"10.1111","volume":"23","author":[{"given":"JP","family":"Ortonne","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Ganslandt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P","family":"Nordin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K","family":"Kragballe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Segaert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2009,7,6]]},"reference":[{"key":"e_1_2_7_2_2","first-page":"396","article-title":"Natural history and treatment of scalp psoriasis","volume":"49","author":"Farber EM","year":"1992","journal-title":"Cutis"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.033217"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1159\/000092283"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.2165\/00128071-200102030-00005"},{"key":"e_1_2_7_6_2","volume-title":"Hair and Scalp Disorders. Common Presenting Signs, Differential Diagnosis and Treatment","author":"Dawber R","year":"1995"},{"key":"e_1_2_7_7_2","unstructured":"National Psoriasis Foundation Benchmark Survey. Available at:http:\/\/www.psoriasis.org\/files\/pdfs\/press\/npfsurvey.pdf(Last accessed: September 2007)."},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3999(00)00210-5"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4362.1993.tb02790.x"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2005.11.1103"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1159\/000018026"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200161110-00006"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1159\/000246851"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1159\/000051731"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1159\/000096069"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2005.01343.x"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2006.07236.x"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.2165\/00128071-200304040-00001"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(99)80057-7"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1159\/000130425"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2008.04.027"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133"},{"key":"e_1_2_7_23_2","doi-asserted-by":"crossref","unstructured":"KragballeK HoffmannV OrtonneJP TanJ NordinP SegaertS.Efficacy and safety of calcipotriol plus betamethasone dipropionate scalp formulation compared with calcipotriol scalp solution in the treatment of scalp psoriasis.Br J Dermatol2008Accepted for publication.","DOI":"10.1111\/j.1365-2133.2009.09116.x"},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1087-0024.2004.09115.x"},{"key":"e_1_2_7_25_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2006.01770.x"},{"key":"e_1_2_7_26_2","volume-title":"How to Score Version 2 of the SF\u201036\u00ae Health Survey","author":"Ware JE","year":"2000"},{"key":"e_1_2_7_27_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02737863"},{"key":"e_1_2_7_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0167-6296(01)00130-8"},{"key":"e_1_2_7_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(99)70112-X"},{"key":"e_1_2_7_30_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.138.9.1221"},{"key":"e_1_2_7_31_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2007.02424.x"},{"key":"e_1_2_7_32_2","doi-asserted-by":"publisher","DOI":"10.1080\/00015550252948194"},{"key":"e_1_2_7_33_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.2002.04967.x"},{"key":"e_1_2_7_34_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2004.06134.x"},{"key":"e_1_2_7_35_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.140.4.408"},{"key":"e_1_2_7_36_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2005.06948.x"},{"key":"e_1_2_7_37_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2006.07237.x"},{"key":"e_1_2_7_38_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2007.08236.x"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1468-3083.2009.03221.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1468-3083.2009.03221.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T21:59:43Z","timestamp":1697061583000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1468-3083.2009.03221.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,7,6]]},"references-count":37,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2009,8]]}},"alternative-id":["10.1111\/j.1468-3083.2009.03221.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1468-3083.2009.03221.x","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,7,6]]}}}